Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)

被引：0

作者：

Izutsu, K. ^{[1
]}

Akahane, D. ^{[2
]}

Toubai, T. ^{[3
]}

Saito, T. ^{[4
]}

Mishima, Y. ^{[5
]}

Fujisaki, T. ^{[6
]}

Kitawaki, T. ^{[7
]}

Kumode, T. ^{[8
]}

Suehiro, Y. ^{[9
]}

Ishitsuka, K. ^{[10
]}

Conlon, R. ^{[11
]}

Noguchi, H. ^{[12
]}

Buchbjerg, J. ^{[13
]}

Favaro, E. ^{[13
]}

Fukuhara, N. ^{[14
]}

机构：

[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[2] Tokyo Med Univ, Dept Hematol, Tokyo, Japan

[3] Yamagata Univ, Div Hematol & Cell Therapy, Fac Med, Yamagata, Japan

[4] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan

[6] Matsuyama Red Cross Hosp, Japan Red Cross Soc, Dept Hematol, Matsuyama, Ehime, Japan

[7] Kyoto Univ Hosp, Dept Hematol & Oncol, Kyoto, Japan

[8] Kindai Univ, Dept Hematol & Rheumatol, Osaka, Japan

[9] Natl Hosp Org Kyushu Canc Ctr, Dept Hematol & Cell Therapy, Fukuoka, Japan

[10] Kagoshima Univ Hosp, Dept Hematol & Rheumatol, Kagoshima, Japan

[11] AbbVie, N Chicago, IL USA

[12] Genmab KK, Tokyo, Japan

[13] Genmab AS, Copenhagen, Denmark

[14] Tohoku Univ, Dept Hematol, Sendai, Miyagi, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.07.548

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO20-2

引用

页码：S1337 / S1337

页数：1

共 50 条

[41] Efficacy controls and long-term follow-up of patients (pts) treated with rituximab for relapsed or refractory, low-grade or follicular (R-LG/F) NHL.
McLaughlin, P
Grillo-López, AJ
Maloney, DG
Link, BK
Levy, R
Czuczman, MS
Cabanillas, F
Dallaire, BK
White, CA
BLOOD, 1998, 92 (10) : 414A - 415A
[42] Long-Term Follow-Up Shows Benefits of Anastrozole
不详
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (03) : 484 - 484
[43] Epcoritamab plus GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
Cordoba, Raul
Jorgensen, Judit
Belada, David
Costello, Regis
Trneny, Marek
Vitolo, Umberto
John Lewis, David
Karimi, Yasmin H.
Sureda, Anna
Andre, Marc
Wahlin, Bjorn E.
Lugtenburg, Pieternella J.
Jiang, Tony
Abbas, Aqeel
Song, Yaou
Risum, Malene
Brody, Joshua D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S468 - S469
[44] Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Phillips, Tycel
Thieblemont, Catherine
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Do, Young Rok
Feldman, Tatyana A.
Gasiorowski, Robin
Jurczak, Wojciech
Kim, Tae Min
Lewis, David John
van Der Poel, Marjolein
Poon, Michelle Limei
Kilavuz, Nurgul
Stirner, Mariana Cota
Soong, David
Chiu, Christopher
Chen, Menghui
Sacchi, Mariana
Elliot, Brian
Hutchings, Martin
Lugtenburg, Pieternella
BLOOD, 2022, 140 : 9443 - 9445
[45] Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma
Berglund, Å
Enblad, G
Carlson, K
Glimelius, B
Hagberg, H
EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 65 (01) : 17 - 22
[46] Lexis: An R Class for Epidemiological Studies with Long-Term Follow-Up
Plummer, Martyn
Carstensen, Bendix
JOURNAL OF STATISTICAL SOFTWARE, 2011, 38 (05):
[47] Long term follow-up after autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma
Stamatoullas, A.
Lanic, H.
Contentin, N.
Nunes, K.
Picquenot, J. M.
Bastard, C.
Tilly, H.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 78 - 78
[48] Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy
Jagadeesh, Deepa
Novelli, Silvana
Luminari, Stefano
Taszner, Michal
Merli, Michele
Xu, Yingzxin
Kamat, Siddhesh
Mastikhina, Liza
Ambati, Srikanth
Chen, Jenny
Chan, Keith
Cope, Shannon
Keeping, Sam
Caisip, Clyde
Mohamed, Hesham
Chaudhry, Aafia
Harnett, James
Bisneto, Jose C. Villasboas
BLOOD, 2024, 144 : 7803 - 7804
[49] Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
Linton, Kim
Jurczak, Wojciech
Lugtenburg, Pieternella
Gyan, Emmanuel
Balari, Anna Maria Sureda
Christensen, Jacob Haaber
Hess, Brian
Tilly, Herve
Cordoba, Raul
Lewis, David
Okada, Craig
Hutchings, Martin
Clausen, Michael Roost
Vitolo, Umberto
Cochrane, Tara
Leppa, Sirpa
Chamuleau, Martine E. D.
Conlon, Rebekah
Favaro, Elena
Gernhardt, Diana
Altintas, Isil
Liu, Yan
Thieblemont, Catherine
BLOOD, 2023, 142
[50] Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Falchi, Lorenzo
Morschhauser, Franck
Gribben, John G.
Huang, Huiqiang
Minh Dinh
Conlon, Rebekah
Chen, Xiaorong
Elliot, Brian
Seymour, John F.
BLOOD, 2022, 140 : 9338 - 9339

← 1 2 3 4 5 →